BLFS250117P25000
- 1.05
- 0.000.00%
BioLife Solutions Newsroom
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Is BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued?
Northland Securities Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $31
Maxim Group Initiates BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $34
Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $31
BioLife Solns Analyst Ratings
Investors Bid BioLife Solutions (NASDAQ:BLFS) up US$53m Despite Increasing Losses YoY, Taking Five-year CAGR to 11%
Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $34
Express News | BioLife Solutions Inc : Maxim Group Raises Target Price to $34 From $30
KeyBanc Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $33
Fluctuations are expected to continue in the early days of Trump's presidency, with Citigroup favoring Medical, Financial, and other defensive Industries.
In the market volatility and uncertainty following Trump's inauguration, defensive industries such as Medical Care and finance are favored in the model portfolio created by Citigroup strategists.
Earnings Call Summary | BioLife Solutions(BLFS.US) Q3 2024 Earnings Conference
Royce Micro-Cap Trust (NYSE: RMT) as of Nov 30, 2024
TD Cowen Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
TD Cowen Remains a Buy on BioLife Solutions (BLFS)
Benchmark Co. Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $30
Biolife Solutions Insider Sold Shares Worth $566,221, According to a Recent SEC Filing
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Jefferies Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
Jefferies Initiates BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $31